There is a great deal of misinformation about silver solutions. While there are several kinds (ionic, colloidal, nano technology, protein silver), the safety of silver is extraordinary, despite the fear of turning blue (argyria) which has been promulgated over the years.
The truth is that virtually no one has ever turned blue because of a deposition of silver particles in the skin. In the documented case where this has happened, the person drank huge and irrational amounts of silver daily for decades. In the recent well-publicized case of a politician who was supposed to have turned blue from drinking silver, it turned out to be a hoax perpetrated by his political opponents in the campaign for office he was participating in.
The smaller the particle size, the more effective the silver is at disrupting the biological function of disease causing bacteria, mycoplasma and viruses. The smaller the particle size, the more efficiently the body can get rid of the silver.
The silver we recommend, ASAP silver sol solution is exceedingly small in size, has never been shown to provide any medical or health problems and has been used for people from infancy to people in their 90s.
Here are the facts as I see them, after extensive experience using silver for infections of all types:
1. Silver in nano sized particles does not cause argyria because the particles are small enough to pass easily out of the urine, rather than being deposited in tissues. No case of argyria has ever been reported with nano particle silver
2. As you said, the amounts you would have to consume border on the insane.
3. Nano silver is effective, without any known side effects, against every pathogen it has been tested against
4. Through its applications in Africa, we know that pregnant women, tiny babies, fragile elderly, people with diabetes, cancer, auto immune disease, etc., do not develop side effects when they take silver as directed.
5. No ulcers have ever been reported with nano silver
6. The silver we recommend has been shown NOT to kill beneficial bacteria, thus protecting the integrity of the gut and the immune system.
ASAP silver sol solution has been tested against more than 650 pathogenic organisms and has been effective in vitro (in the lab) against every one. It has also been tested against the normal bacteria (which we refer to collectively as “pro biotics”) and found, rather amazingly, to spare these beneficial bacteria.
I personally never travel without ASAP silver sol solution. I have used it for common ailments like a cold and uncommon ones like malaria. It can be taken via sub lingual administration directly under the tongue to speed absorption and prevent it from reaching the GI tract or it can be mixed in a small amount of water and taken by mouth. It has no flavor or taste so even babies can take it without distress.
We have concluded a special arrangement with Nutronix.com to allow us to offer you this silver sol solution. Please do yourself a favor and lay in a good supply of this outstanding health aid.
Click here, http://www.Nutronix.com/naturalsolutions, to get your supply. Click on the “Products” tab, then go to the left hand column and click on “Silver Solutions”.
It is not clear how long the FDA will allow this exceptional product to remain on the market. I suggest you stockpile it for pandemics, general disease use and immune system boosting.
Yours in health and freedom,
Dr. Rima
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMarketPlace.org
www.NaturalSolutionsMedia.tv
Effect of Prophylactic Treatment with ASAP-AGX-32 and ASAP Solutions on an Avian Influenza A (H5N1) Virus Infection in Mice
Gordon Pedersen,American Biotech Labs
Sidwell, Robert W., The Institute for Antiviral Research of Utah State University Animal, Dairy and Veterinary Sciences Dept
Alan Moloff, D.O., M.P.H., Colonel, MC, U.S. Army (RET)
Robert W. Saum Ph.D., IDHA, Medical Science and Technology, American Biotech Labs
Introduction
Avian Influenza (H5N1, or Bird Flu) can be a fatal disease in humans and a serious threat to become a pandemic event. Since there is no pharmaceutical remedy for the Bird Flu it is essential that preventive treatments be tested and developed in order to enhance survivor rates in the human population.
Since 1973, Silver has been shown to have topical activity against 22 bacterial species (643 isolates) including gram positive and gram negative bacteria1. As an antimicrobial agent, Silver has been shown to be beneficial in the treatment and prevention of burn infections, post surgical wound infections, and gynecological infections2, 3. In addition, Silver has been shown to be active against black mold4, Anthrax5, Bubonic plague6, Malaria7, and numerous viruses such as Hepatitis 8.
Recently it was reported that the American Biotech Labs product, Silver Sol, demonstrated additive and synergistic effects when combined in individual trials with 19 different antibiotics9. The Silver
from ABL was shown to improve the effectiveness of the antibiotics even against
antibiotic resistant infections 9.
The Merck Index identifies the following medicinal uses of silver: Antiseptic particularly for mucous membranes and infectious sinusitis10. The Merck Manual and Centers for Disease Control, recommend that Silver nitrate drops should be placed in each infant eye as soon as possible or at least in the first half hour of life to prevent gonorrheal ophthalmia 11.
The safe use of Silver as an orally consumed preventive agent has been demonstrated and supported by reports from the EPA and the United States Department of Health and Human Services in a 76 week long study12,13. Dogs that inhaled Silver showed activity in the lung in one hour with 90% of the silver carried to the liver by the blood within 6 hours14.
Due to the increased risk from methicillin resistant bacteria, black mold, plasmodium and especially bird flu, the need for orally consumed, safe, daily prophylactic prevention exists. In this study, Silver Sol from American Biotech Labs demonstrates safe beneficial and preventive activity against H5N1 Bird Flu, when taken orally in mice.
The American Biotech Labs product, ASAP- AGX-32, as well as their product designated ASAP, to be virucidal against the avian influenza A/Vietnam/1203/2004 (H5N1) x A/Ann Arbor/6/60 hybrid virus, with an up to 2 log10 virus titer reduction occurring after a 6 h incubation of the product and the virus
(USU report dated March 28, 2006). In that same report, similar incubation with the avian influenza A/Duck/MN/1525/81 (H5N1) virus reduced the virus titer by approximately one-half log10 in the same
time period. This material is reportedly very well tolerated in human subjects when ingested orally, Dr Gordon Pedersen of American Biotech Labs designed a study with the Centers for Antiviral Research to
evaluate the potential for ASAP-AGX-32 and ASAP, to inhibit an avian influenza A (H5N1) virus infection of mice when administered orally to the animals beginning 1 week prior to virus exposure. This report describes the results of this experiment.
Materials and Methods
Animals: Female specific pathogen-free 18- 21 g BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA). They were quarantined 5 days prior to use. They were housed in polycarbonate cages with stainless steel tops and provided tap water and mouse chow ad libitum.
Virus: Influenza A/Duck/MN/1525/81 (H5N1) virus was originally provided by Dr Robert Webster of the St. Jude Hospital (Memphis, TN). The virus was adapted to mice by passage twice through weanling animals and a large pool prepared in MDCK cells for use in this study. The virus was titrated in young
adult mice prior to use in the present experiment.
Compounds: ASAP and ASAP-AGX-32 were provided by Dr Pedersen. They were in blue bottles, so all studies run with each were performed using the materials in injection bottles covered with aluminum foil to avoid light exposure. All were stored at room temperature until used. It is understood that the ASAP solution contained a colloidal silver at a concentration of 10 ppm, and the ASAP-AGX-32 contained the same colloidal silver at a concentration of 32 ppm. Ribavirin, included as a known positive
control, was provided by ICN Pharmaceuticals, Inc. (Costa Mesa, CA); it was dissolved in sterile saline and stored at 4o C until used.
Arterial Oxygen Saturation (SaO2) Determinations: SaO2 was determined using the Ohmeda Biox 3800 pulse oximeter (Ohmeda, Louisville, OH). The ear probe attachment was used, the probe paced on the thigh of the animal. Readings were made after a 30 sec stabilization time on each animal. Use of an earlier Ohmeda Model (3740) for measuring effects of influenza virus on SaO2 in mice has been previously described by Dr.s Sidwell and Pedersen15.
Lung Score Determinations: Each mouse lung removed and placed in a petri dish which, using a permanent black marker, had been divided into sections which were pre- numbered from 1 through 3 or, for placebo controls, 1 through 5. Each lung was assigned a score ranging from 0 (normal appearing lung) to 4 (maximal plum coloration in 100% of lung). These scores were assigned blindly, with the individual doing the scoring not being aware of what group was being examined. An arithmetic mean was determined for each group.
Lung Virus Titer Determinations: Each mouse lung was homogenized and varying dilutions assayed in triplicate for infectious virus in MDCK cells as described previously16. Each lung homogenate was
centrifuged at 2000 g for 5 min and the supernatents used in these assays.
Experimental Design: Groups of 19 mice were treated by oral gavage (p.o.) with either ASAP-AGX-32 or ASAP twice daily (every 12 h) for 7 days, then infected intranasally (i.n.) with an LD70 dose of
influenza virus, then treated an additional 10 days. A similar group of mice were treated p.o. with ribavirin at a dosage of 75 mg/kg/day twice daily for 5 days beginning 4h pre-virus exposure. The infection was achieved by anesthetizing the mice with an intraperitoneal injection of Ketamine at a dosage of 100 mg/kg and instilling 90 µl of suspended virus in minimum essential medium on the nares of the animals. As controls, 35 mice were treated with water using the identical schedule as used for the
ASAP materials and infected as above. Ten infected, test substance-treated mice and 20 water-treated controls were observed daily for deaths for 21 days after virus exposure, and SaO2 levels ascertained on days 3-11, which were the times when this parameter usually declines. From the remaining infected, treated animals, 3 test substance-treated and 5 water-treated control mice were killed on days 1, 3 and 6, and their lungs removed, assigned a consolidation score, weighed, and assayed for virus titer.
As toxicity controls, 3 uninfected mice were treated in parallel with each test material and observed for signs of adverse effects for 21 days. The weights of these mice as well as 5 normal controls were determined prior to initial treatment and again 18 h after final treatment to determine if the treatments
affected host weight gain. Three normal controls were also sacrificed on days 3 and 6 to provide background lung data.
Statistical Analysis
Increases in total survivors were evaluated by chi square analysis with Yates’ correction. Increases in
mean day to death, differences in mean SaO2 values, mean lung weight, and mean virus titers were analyzed by t-test. Only animals dying up to day 21 were considered for mean day to death calculations. The Wilcoxon ranked sum analysis was used for mean lung score comparisons. Each
statistical test was run using Excel software on a MacIntosh computer.
Results and Discussion
The results of this experiment are summarized in Table 1 and in Figures 1-4. As seen in Table 1, the virus challenge in this experiment was lethal to 14 of the 20 placebo-treated mice, with the mean day to
death being 8.4 days. Such a pattern of death is considered ideal for evaluation of potential antiviral agents. This optimal condition was verified by the observation that Ribavirin was fully protective to the
mice, preventing any deaths from occurring (Table 1), significantly lessening SaO2 declines (Figure 1), inhibiting lung score development (Figure 2), lung weight increase (Figure 3), and lung virus titer
increases (Figure 4).
Treatment with ASAP-AGX-32 appeared to not affect the numbers of animals dying of influenza, although a half-day delay in mean day to death was seen (Table 1). SaO2 declines in this group of treated mice were almost at the same rate as those in the placebo controls, although it was interesting
that on the first day this parameter was assayed, a highly significant (P<0.001) difference was seen (Figure 1). SaO2 declines are a manifestation of declining lung function, suggesting that the lung consolidation in the lungs did not progress as rapidly as seen in the placebo controls. The treatment appeared to moderately lessen lung consolidation as seen by lower lung scores on each time evaluated, the day 6 mean lung score being significantly (P<0.05) less than the placebo treated controls (Figure 2). Lung weights, another indication of fluid developing in the lungs to cause pneumonia in the animal, were also less at each time point than seen in the placebos (Figure 3). The mean lung virus titers in the
mice treated with ASAP-AGX-32 were lower than the placebo controls on days 3 and 6 of the infection (Figure 4).
Treatment with ASAP, which we understand is a less-concentrated version of ASAP-AGV- 32, also provided some intriguing results. Especially of interest was the observation that 60% of the infected mice treated with this compound survived compared to the 30% in the placebo-treated controls. Although not statistically significant because of the number which survived in the latter controls, this effect is strongly suggestive a disease-inhibitory effect may have occurred. At two time points during the SaO2 assays, days 3 and 6, the declines normally seen were significantly lessened (P<0.01), and
there was a general lessening of decline throughout the times of assay (Figure 1). Modest inhibition in lung scores were seen in this treated group as well, especially on day 6 (Figure 2); the lung weight data did not correlate too well with the lung scores, however (Figure 3). Again, slight inhibition of lung virus titers were seen in the ASAP- treated, infected mice (Figure 4).
Both the ASAP formulations were well tolerated by the toxicity control mice as seen by no deaths occurring in them and host weight increases observed during time of therapy. Ribavirin, while not lethal to the mice, did result in a 0.4 g host weight loss (Table 1); this was an expected effect for the latter material, since the maximum tolerated dose is approximately 100 mg/kg/day.
It is difficult to attribute the effects seen in this experiment wholly to viral inactivation, since both test materials were administered orally to animals infected by direct nasal inhalation, although the treatments began one week before virus exposure, so it is possible that a portion of the Silver Sol may
have been able to be in the vicinity of the virus-exposed lung tissue. It is also possible that this material is exerting a mild immunomodulatory effect in the animals, which would provide modest protection
against the infection. If such a mechanism is indeed associated with the potential activity seen, then a different treatment schedule, perhaps limiting the number of treatments to one per day or once every other day, may enhance any immune modulatory effects, since it is recognized that too-frequent dosing may overtax the immune system. The greater protection seen by the lower- dosed ASAP material could be explained by immunomodulation, since the greatest immunologic effect is not necessarily at the
highest dose used.
Another mechanism whereby the ASAP materials may have inhibited the influenza virus infection in these studies may simply be one of coating the virion with Silver Sol to prevent attachment and penetration. Again, the material would need to be in the vicinity of the exposed lung tissues at the time
infection was initiated. The Silver material could also play a role in limiting apoptosis of the epithelial lining of the lung induced during acute lung inflammation. Apoptosis plays a causative role in acute lung injury in part due to epithelial cell loss.
Further studies would have to be conducted to more fully delineate the actions of this material.
It is acknowledged that the effects seen in the present study, while of considerable interest, would need to be repeated to confirm that the observations were not due to mere chance. Consideration of combined use of oral administration of the ASAP materials and intranasal instillation at near
the time of virus exposure would determine
whether the effects seen were indeed
associated with virucidal effects of these
materials.
Summary
Mice infected with avian influenza A/Duck/MN/1525/81 (H5N1) virus were treated with the Silver Sol-containing formulations ASAP-AGX-32 and ASAP provided by American Biotech Labs. Oral gavage treatment began 7 days prior to virus exposure and continued twice daily for a total of 17 days. Treatments with both formulations provided a suggested inhibitory and preventive effect on this virus infection as seen by either less animals dying in the treated groups than in the placebo-treated
controls, delay in mean day to death, lessened SaO2 decline, modest inhibition of lung consolidation, and/or lessened virus titers in the lungs. Ribavirin was included as a positive control drug, used orally at a dose of 75 mg/kg/day twice daily for 5 days beginning 4 h pre-virus exposure, and this treatment was markedly inhibitory to the infection as expected.
References
1. Carr, H., Wlodowski, T., 1973. Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York. Antimicrobial Agents and Chemotherapy. 10:585-587.
2. Fox, C. J. Jr., 1968. Silver sulfadiazine, a new topical therapy for Pseudomonas burns. Arch. Surg. 96:184-188.
3. Fox, C. J., 1969. Control of Pseudomonas infection in burns by Silver Sulfadiazine. Surg.Gynecol. Obstet. 128:1021-1026.
4. U.S. House International Relations Committee, 2005. Written testimony on Black Mold.
5. Illinois Institute of Technology. 2001. Anthrax.
6. Robinson, R., 2003. Bactericidal activity of ASAP Silver Solution on Yersinia Pestis, the etiological agent of plague. Department of Microbiology, Brigham Young University.
7. U.S. House Relations Committee. 2005. Written testimony on Malaria.
8. Hafkine, A., 2003. ASAP antiviral activity in Hepatitis B; DNA Polymerase Inhibition, Reverse Transcriptase Inhibition. Hafkine Institute for Training, Research and Testing.
9. DeSousa, A., Mehta, D., Leavitt, R. W., 2006. Bactericidal activity of combinations of silver-water dispersion with 19 antibiotics against seven microbial strains. Current Science. 91:7- 11.
10. Merck Index, 2006. Silver 1:645.
11. Merck Index, 2006. Silver 1:2082.
12. EPA Research and Development, 1988. Drinking water criteria document for Silver. Office of Health and Environmental Assessment.
13. U.S. Department of Health and Human Services, Public Health Service and Agency for Toxic Substances and Disease Registry, 1990. Toxicological profile on Silver.
14. Phalen, R.F. and Morrow P.E., 1973. Experimental Inhalation of Metallic Silver, Health Physics 24: 509-518.
15. Sidwell, R.W., Huffman, J. H., Gilbert, J., Moscon, B. Pederson, G., Burger, R. and Warren, R.W. 1992. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza
virus in mice. Antimicro Agents Chemother 36:473-6.
16. Sidwell, R.W., Huffman, J. H., Call, E.W., Alaghamandan, H., Cook, P.D, and Robins, R.K. 1985. Effect of Selenazofurin on influenza A and B virus infections in mice. Antiviral Res. 6:343-353.
Another theoretical “impossibility†becomes real by experiment. Water burning? Yes, it can!
Materials Research Innovations, March 2008, Vol 12, 3-5.
Table 1. Expt. ABLA-1. Effect of Oral Gavage Prophylactic Treatment with ASAP-AGX-32 and ASAP on an Influenza A (H5N1) Virus Infection in Mice.
Animals: Female 18-21 g BALB/c mice Virus: Influenza A/Duck/MN/1525/81 (H5N1) Drug diluent: Company diluent Treatment schedule: bid x 17 beg -7 days (Ribavirin: bid x 5 beg -4 h) Treatment route: p.o. Experiment. duration: 28 days Tax Controls Infected, Treated Mice Tax Controls Dosage
Surv/Total Mean Host Weight Change (g) Surv/Total Mean Day to Death ± SD Mean Day 11
SaO2 (% =± SD) ASAP- AGX- 32 32ppm 3/3 1.8 2/10 8.9 ± 1.4 75.4 ± 1.0
ASAP 10ppm 3/3 1.4 6/10 7.3 ± 1.0 76.7 ± 2.1 Ribavirin 75 mg/kg /day 3/3 -0.4 10/10*** >21.0 ± 0.0*** 86.6 ± 2.5** * H2O — — — 6/20 8.4 ± 1.8 76.0 ± 1.9 Norma l Contro ls — 5/5 2.3 — — 88.8 ± 3.0
Difference between initial weight and weight 18 h after final treatment.
Difference between initial weight and weight 18 h after final treatment.
*P<0.05; **P<0.01; ***P<0.001 compared to H2O -treated controls.
Volcan, Panama (PRWEB), September 23, 2008
Washington, September 21, 2008 – After a few cryptic reports in the European media over the Summer, the story of the two influenza biochemistry researchers who were brutally killed in London June 29, 2008 has finally broken in the U.S. press in mid September.
On July 4th the Times of London online reported, “As two talented biochemistry students and close friends, Laurent Bonomo and Gabriel Ferez had come to London to develop their skills as specialists in infectious disease and environmental engineering. Instead the two became the victims of an attack that, even by the standards of a city battling against the blight of knife crime, is among the most horrific in living memory…” The students had been tortured and stabbed hundreds of times.
http://www.timesonline.co.uk/tol/news/uk/crime/article4265622.ece
The deaths had been announced on the Imperial College of London web site on July 3, 2008.
http://www3.imperial.ac.uk/rector/announcements/3july2008
But on the same date, certain European online sources were reporting, “France’s General Directorate for External Security (DGSE) is reporting today that one of their top avian flu researchers, Laurent Bonomo, and his French roommate Gabriel Ferez have been brutally murdered in London..” This claim appears to have started with “Sorcha Faal” a well-known Internet rumor-monger pseudonym.
http://conspiracycentral.info/index.php?showtopic=22584&mode=threaded
By July 5th the mainstream media was reporting a “PlayStation theft” alleged motive for the murders.
http://www.timesonline.co.uk/tol/news/uk/crime/article4268716.ece
A July 6th report continues, “Bonomo had been working on investigating the deadly H5N1 Avian Flu Virus at London’s Imperial College. An interesting incident preceding these horrors was the theft of Mr. Bonomo’s laptop the previous week. One wonders what might have been found on that and whether it had anything to do with his subsequent demise?”
http://whistleblowersbc.blogspot.com/2008/07/global-cull-list.html
We cannot confirm the DGSE involvement, as this French agency does not issue press releases, but the BBC apparently supports the claim for Avian Flu research involvement, stating the victims were involved in “a research project into chains of protein within DNA at Imperial College”
http://news.bbc.co.uk/2/hi/uk_news/england/london/7487126.stm
This story finally reached the U.S. through the patriot journal, American Free Press. Its September 29, 2008 edition reports, “Two French biochemical students, Laurent Bonomo and Gabriel Ferez, were murdered by Israeli Mossad-British intelligence assassination teams on June 29, 2008. Both Bonomo and Ferez were studying at the prestigious London Imperial College researching the origins of bird flu and the link to the alleged vaccines.”
The news magazine further asserts, “The two researchers had discovered that the alleged bird flu vaccine, H-7, which was designed to neutralize and stop the H5N1 avian flu virus, had been spliced using DNA to actually create a vaccine and an illness producing virus at the same time. The French students had also discovered that the bird flu vaccine, i.e. a virus, had links to U.S., British and Israeli laboratories…”
http://www.americanfreepress.net/html/bio-chemists_murdered_149.html
The Natural Solutions Foundation has been following many stories information regarding the weaponization of the Avian Flu into a pandemic form since we broke the Weaponized Avian Flu story on July 19, 2008. We have pointed out that the recent delivery to the United States of a “Pandemic Avian Flu Vaccine” (just after Homeland Security and Health and Human Services each issued a Guideline on Pandemic Flu Vaccination Allocation in late July) would not be possible without a pandemic version of the Avian Flu virus, a virus that does not (yet) exist in nature. The Foundation points out that is a principle of virology that a vaccine cannot be produced unless its target organism already exists.
http://www.pandemicflu.gov/vaccine/allocationguidance.pdf
Therefore we consider the murder of two of the people researching the weaponization of the influenza virus as very troubling, if it indeed has happened. Substantial funding is being made available to laboratories around the world, through agencies such as the Wellcome Trust, to explore how and why the Avian Flu has not (yet) become pandemic. The Natural Solutions Foundation asks how many laboratories conducting these dangerous experiments would it take to be assured that the weaponized virus would escape into the environment, perhaps helped, like the 2001 Anthrax panic, by a disgruntled employee? What information is on the laptop stolen from the victims? Why were they tortured before they were killed?
http://www.wellcome.ac.uk/News/Media-office/Press-releases/2008/WTX050374.htm
In the interests of the well being of the general population who are at risk in the event of an engineered pandemic, we urge the American Free Press to share the background information and sources of the highly disturbing and, if true, significant information in order to to substantiate and disseminate such information as widely as possible. The Natural Solutions Foundation believes we may be seeing the unraveling of a poorly-constructed scenario.
Further information: www.GlobalHealthFreedom.org and www.HealthFreedomUSA.org
Current Estimate of Situation: http://drrimatruthreports.com/?p=965
The heat is on: against a growing background beat of “Pandemic’s nearly here, pandemic’s nearly here!” the repeated refrain of “Vet more vaccinations, get more shots!” is getting louder, too.
This time, we have a speculative paper that strikes me as absurd in which children are placed at high risk for getting vaccinated with yet more untested, potentially dangerous and very, very profitable vaccinations. In this case, the call is for saving the lives of children by vaccinating them with vaccines which contain deadly poisons like mercury, formaldehyde, fetal DNA, steal viruses, fluoride, chrolides, aluminum, etc., for a disease whose impact is vastly overstated (see “Flu Shot Does Not Reduce Risk of Death” following and not particularly the analysis of statistical conclusions about the death rate from flu. The highly absurd figure of 36,000 deaths per year from flu is used to sell flu vaccines and fear. But all, that’s right, all, deaths from pneumonia or any other possibly flu-related cause, whether it is or is not actually related to flu, is counted as a flu death in the grim sales pitch: get vaccinated or die.
As this second article cited shows, the reality, when examined closely, is nowhere near the puffery.
Well, what would you expect from a propaganda campaign?
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org
Vaccinating Younger Population Minimizes Life-Years Lost to Influenza
NEW YORK (Reuters Health) Sept 05 – Shifting the current vaccination strategy to target younger populations would reduce the number of years of life lost (YLL) to influenza, according to a report in the August 1st issue of The Journal of Infectious Diseases.
Vaccination allocation policy has been the subject of debate in light of several issues, among them the criticism by bioethicists of the inherent axiom that any life lost has the same value, regardless of the age of the deceased, the authors explain.
Dr. Mark A. Miller from the National Institutes of Health, Bethesda, Maryland, and colleagues sought to provide an alternative quantitative tool to help guide pandemic vaccine priority setting and achieve the greatest possible population impact, by preventing the loss of as many years of life as possible.
For a 1918-like pandemic scenario, in which most YLL occur for the younger age groups, the optimal vaccination group comprises people younger than 45 years, according to the models employed.
For a 1957-like epidemic, in which YLL were similar for older and middle age groups, it is unclear whether vaccinating the middle-age group would be better than vaccinating seniors, leading the investigators to conclude “that these age groups would be equally good choices.”
For a mild 1968-like influenza epidemic, the researchers note, vaccinating people 45 to 64 years old represents the optimal strategy for minimizing YLL.
“Our estimation is not an endorsement of any particular policy but highlights how the choice of health outcome metrics such as YLL can influence the prioritization of age groups to vaccinate in pandemic settings,” the authors explain. “It also shows that the vaccine priority scheme for seasonal influenza is not optimized to mitigate the impact of pandemic influenza.”
“These results suggest the need for pandemic plans to have an element of flexibility that allows the prioritization of age groups for immunization at the start of a pandemic to be modified as age-specific epidemiological data on the novel virus become available in real time,” the researchers conclude.
“Equally important, the question of who should be vaccinated first needs to be debated and reasoned through now, before the onset of a public health emergency, while we have the time to reflect on which decision-making metric is the most appropriate,” they add.
J Infect Dis 2008;198:305-311.
Flu Shot Does Not Reduce Risk Of Death, Research Shows
ScienceDaily (Aug. 31, 2008)  The widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny, according to researchers in Alberta. The vaccine does confer protection against specific strains of influenza, but its overall benefit appears to have been exaggerated by a number of observational studies that found a very large reduction in all-cause mortality among elderly patients who had been vaccinated.
The study included more than 700 matched elderly subjects, half of whom had taken the vaccine and half of whom had not. After controlling for a wealth of variables that were largely not considered or simply not available in previous studies that reported the mortality benefit, the researchers concluded that any such benefit “if present at all, was very small and statistically non-significant and may simply be a healthy-user artifact that they were unable to identify.”
“While such a reduction in all-cause mortality would have been impressive, these mortality benefits are likely implausible. Previous studies were likely measuring a benefit not directly attributable to the vaccine itself, but something specific to the individuals who were vaccinatedâ€â€a healthy-user benefit or frailty bias,” said Dean T. Eurich,Ph.D. clinical epidemiologist and assistant professor at the School of Public Health at the University of Alberta. “Over the last two decades in the United Sates, even while vaccination rates among the elderly have increased from 15 to 65 percent, there has been no commensurate decrease in hospital admissions or all-cause mortality. Further, only about 10 percent of winter-time deaths in the United States are attributable to influenza, thus to suggest that the vaccine can reduce 50 percent of deaths from all causes is implausible in our opinion.”
Dr. Eurich and colleagues hypothesized that if the healthy-user effect was responsible for the mortality benefit associated with influenza vaccination seen in observational studies, there should also be a significant mortality benefit present during the “off-season”.
To determine whether the observed mortality benefits were actually an effect of the flu vaccine, therefore, they analyzed clinical data from records of all six hospitals in the Capital Health region in Alberta. In total, they analyzed data from 704 patients 65 years of age and older who were admitted to the hospital for community-acquired pneumonia during non-flu season, half of whom had been vaccinated, and half of whom had not. Each vaccinated patient was matched to a non-vaccinated patient with similar demographics, medical conditions, functional status, smoking status and current prescription medications.
In examining in-hospital mortality, they found that 12 percent of the patients died overall, with a median length of stay of approximately eight days. While analysis with a model similar to that employed by past observational studies indeed showed that patients who were vaccinated were about half as likely to die as unvaccinated patients, a finding consistent with other studies, they found a striking difference after adjusting for detailed clinical information, such as the need for an advanced directive, pneumococcal immunizations, socioeconomic status, as well as sex, smoking, functional status and severity of disease. Controlling for those variables reduced the relative risk of death to a statistically non-significant 19 percent.
http://www.sciencedaily.com/releases/2008/08/080829091323.htm
Mass graves, a 17 week delay between death and burial, schools closed for 10 weeks while hundreds of thousands or even millions of people die in a 15 week nightmare in the UK.
Yes, a successful weaponised Avian Flu certainly can ruin your day unless you happen to be a One World Government Globalist with depopulation tendencies, of course.
Look at what the British Government is planning for and recall that there is not a single human case of Avian Flu, let alone a death, anywhere in Europe and then tell me that this makes sense. Because to me this sounds exactly like more Psy Ops – “Soften ’em up, get them used to the idea and make ’em really afraid. Then you can do whatever you want with them”
Well, not me and not you.
The more that we disseminate our skepticism and our accurate information, the harder the job of the fear mongers becomes.
Gullibility is their tool and their friend.
Knowledge is ours.
Please make sure that everyone you know signs up for the informative and important free and secure Health Freedom eAlert, http://drrimatruthreports.com/index.php?page_id=187. It’s free and its filled with information that we need to disseminate widely.
Speaking truth to power is our protection. We are the Power, after all.
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org
London – Britain is considering mass human burials should a bird flu pandemic break out, The Sunday Times newspaper said.
A “prudent” worst-case assessment suggested 320 000 people could die in Britain if the H5N1 virus mutated into a form contagious to humans, according to a confidential Home Office report seen by the weekly.
Titled Managing Excess Deaths in an Influenza Pandemic and dated March 22, [2008] the document reportedly says that such a large number of deaths could lead to delays of up to 17 weeks in burying or cremating victims.
It warned that “common burial” would stir up images of the mass burial pits used during the Great Plague of 1665.
But in fact it “might involve a large number of coffins buried in the same place at the same time, in such a way that allowed for individual graves to be marked”.
The Sunday Times weekly said the report had been discussed last week in a cabinet subcommittee chaired by Health Secretary Patricia Hewitt.
Avian influenza is lethal to poultry and dangerous for humans in close proximity to infected fowl. It has claimed more than 100 lives, according to a World Health Organisation toll.
But, apart from a few anecdotal cases, the mortality has occurred exclusively by direct transmission from birds to humans and not among humans themselves. To acquire that contagiousness would open the way to a pandemic.
The report suggests that local authorities could cope with a “base case” of 48 000 deaths in England and Wales in a 15-week pandemic.
But it warned: “Even with ramping local management capacity by 100 percent, the prudent worst case of 320 000 excess deaths is projected to lead to a delay of some 17 weeks from death to burial or cremation.”
Should the outbreak kill 2.5% of those who contract the flu, it added, “no matter what emergency arrangements are put in place there are likely to be substantially more deaths than can be managed within current timescales”.
It said vaccines would not be available in the first wave of a pandemic, and possibly longer, and should not be seen as a “silver bullet”.
The report suggests schools would have to close for up to 10 weeks because children would be “super-spreaders” of bird flu.
The Home Office said it did not comment on leaked documents.
A spokesperson added: “The government is taking seriously the possible threat of an influenza pandemic in the light of the global situation and the possibility that a novel strain of the influenza virus could emerge.
“Prudent precautionary planning is under way across all elements of the response, including the health service, other essential services and local authorities.”
The H5N1 virus has been detected in nearby France.
Last week a health official in Goma, Nigeria, stated that Bird Flu, which has killed not one person in Goma, Nigeria or Africa, is “Deadlier than AIDS”. This week, in the Philippines, bird trappers are urged to stop their practice because of Bird Flu. The Philippines, like Nigeria and every other country in Africa, has never had a single case of human Bird Flu.
Don’t get me wrong: I think trapping creatures in the wild is a bad practice and destroying nests and killing birds or selling them for industrial purposes (especially to satisfy the atavistic urge to cage a wild bird for your own amusement) are practices that should be discouraged. But not because of the instigated insanity of public health or other officials given false and misleading information and lured into absurd behavior.
And lest anyone think that this clinical insanity is localized to developing nations, recall that every State in the US, and a great many cities and towns, are “practicing” for the “inevitable” pandemic promised to them by the members of “Official dumb” who are whipping up the fervor and spreading it.
How much money that could be better used for real health and prevention services is being wasted on these endless “exercises” at every level? Nurses are being told that their job is to aid the dying flu victims. Hospitals are being reorganized to house special feverish patients in outpatient wards. UK hospital workers are demanding special hazard suits to work in. The fervor mounts. Not the fever. There is none. That is because there are no cases of Avian Flu.
Meanwhile, the “softening up” of rational thinking, the Psy Ops, continues apace with nonsense like this so frequent that it becomes “normal”. It is not, in my opinion, anything like “normal”. It is a stimulated insanity, the best protection against which is a firm hold on rational thinking.
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org